Patents Assigned to The Green Cross Corporation
  • Patent number: 10444246
    Abstract: Provided are a kit for measuring a titer of a human antibody, a humanized antibody, or a human Fc-fusion protein in human plasma or serum, and a method for measuring a titer of a human Fc-containing protein in human plasma or serum using the same, and more specifically, a kit for measuring a titer of human Fc-containing protein in human plasma or serum, the kit including a diluent for sample, a diluent for conjugate, and a cleansing solution and being used in analysis through an indirect enzyme-linked immunosorbent assay (indirect ELISA), and a method for measuring a titer of human Fc-containing protein in human plasma or serum using the same.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: October 15, 2019
    Assignee: GREEN CROSS CORPORATION
    Inventors: Yong Won Shin, Juho Lee, Jeong-Ae Lim, Ki Hwan Chang, Min-Soo Kim
  • Publication number: 20190169174
    Abstract: The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.
    Type: Application
    Filed: June 15, 2017
    Publication date: June 6, 2019
    Applicants: DAEWOONG PHARMACEUTICAL CO., LTD., GREEN CROSS CORPORATION
    Inventors: Hee-kyoon YOON, Se-Hwan PARK, Ji-Sung YOON, Soongyu CHOI, Hee Jeong SEO, Eun-Jung PARK, Younggyu KONG, Kwang-Seop SONG, Min Ju KIM, So Ok PARK
  • Publication number: 20190153117
    Abstract: Disclosed are epitopes of the epidermal growth factor receptor (EGFR) and the use thereof. The epitopes are highly preserved, and located in the domain closely related to binding with an epidermal growth factor (EGF). Therefore, vaccine compositions comprising the epitopes or compositions comprising antibodies to the epitopes may efficiently block a signal transduction caused by binding of EGF and EGRF, and thus can be highly valuably used in treating various diseases such as cancer. An antibody bound to the epitopes of the present invention may efficiently inhibit binding of various EGFR ligands such as not only EGF but also TGF-?, AR, BTC, EPR and HB-EGF, with EGFR, and therefore can be used in treating various diseases resulting from an activation of EGFR caused by binding not only with EGF but also with other EGFR ligands.
    Type: Application
    Filed: January 28, 2019
    Publication date: May 23, 2019
    Applicants: GREEN CROSS CORPORATION, MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE
    Inventors: Se-Ho Kim, Kwang-Won Hong, Ki-Hwan Chang, Min-Soo Kim, Mi-Jung Lee, Jong-Hwa Won, Min-Kyu Hur, Hyun-Soo Cho, Ji-Ho Yoo
  • Patent number: 10294207
    Abstract: Provided is pyrazole derivatives as a TNIK (Traf2- and NCK-interacting kinase), IKK? (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the pyrazole derivative according to the present invention effectively inhibits TNIK, IKK? and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: May 21, 2019
    Assignee: GREEN CROSS CORPORATION
    Inventors: Soongyu Choi, Kisoo Park, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, Ickhwan Son, Sang-ho Ma, Kwang-Seop Song, Min Ju Kim, So Ok Park, Man-Young Cha, Mi-Soon Kim, Sang Mi Kang, Dong Hyuk Jang, Jangwon Hong
  • Publication number: 20190119388
    Abstract: The present invention provides a pharmaceutical composition for inhibiting the metastasis of cancer, comprising, as an active ingredient, an antibody that specifically binds to an epidermal growth factor receptor, and a method for inhibiting the metastasis of cancer using the composition. The composition or the method is effective in inhibiting the invasion of various gastric cancer cell lines induced by EGFR ligands. Therefore, the pharmaceutical composition can be usefully used for inhibiting the metastasis of cancer.
    Type: Application
    Filed: April 27, 2016
    Publication date: April 25, 2019
    Applicants: GREEN CROSS CORPORATION, MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Jong-hwa WON, Yangmi LIM, Min-Kyu HUR
  • Patent number: 10239873
    Abstract: Provided are 7-azaindole or 4,7-diazaindole derivatives as an IKK? (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor. The 7-azaindole or 4,7-diazaindole derivative effectively inhibits IKK? and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: March 26, 2019
    Assignee: GREEN CROSS CORPORATION
    Inventors: Soongyu Choi, Kwang-Seop Song, Hee Jeong Seo, Sang-ho Ma, Eun-Jung Park, Younggyu Kong, So Ok Park, Kisoo Park, Ickhwan Son, Min Ju Kim, Man-Young Cha, Mi-Soon Kim, Sang Mi Kang, Dong Hyuk Jang, Jangwon Hong
  • Patent number: 10174299
    Abstract: A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter Syndrome.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: January 8, 2019
    Assignees: GREEN CROSS CORPORATION, MediGeneBio Corporation
    Inventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
  • Publication number: 20180346588
    Abstract: The present invention relates to an antibody specifically bound to mesothelin (MSLN), a nucleic acid encoding the antibody, a vector and a host cell including the nucleic acid, a method for producing the antibody, and a pharmaceutical composition for treating cancer or tumor including the antibody as an active ingredient. The antibody specifically bound to the mesothelin according to the present invention has high affinity and specificity to an antigen, such that it is possible to develop an antibody effectively usable for treatment or diagnosis of cancer or tumor diseases.
    Type: Application
    Filed: September 23, 2016
    Publication date: December 6, 2018
    Applicants: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH, GREEN CROSS CORPORATION
    Inventors: Dong-Sik KIM, Eun Jung SONG, Mijung LEE, Eun-Hee LEE, Miyoung OH, Jae Chan PARK, Kisu KIM, Sujeong KIM, Hyung-Kwon LIM, Kyuhyun LEE, Jongwha WON, Soongyu CHOI, Young Seoub PARK
  • Publication number: 20180303914
    Abstract: A Hunter syndrome therapeutic agent contains a first composition to be intravenously injected and a second composition to be subcutaneously injected. The agent can reduce the number of visits to the hospital by patients with Hunter syndrome to twice a month or less. It maintains a medicinal effect equivalent to or greater than that of a conventional once-a-week IV injection, increases drug-taking compliance of patients in comparison to conventional therapeutic agents and treatment methods, and enables enhanced patient welfare and convenience.
    Type: Application
    Filed: July 4, 2016
    Publication date: October 25, 2018
    Applicants: GREEN CROSS CORPORATION, MEDIGENEBIO CORPORATION
    Inventors: Jin-Kyung LEE, Han-Yeul BYUN, Myung-Eun JUNG, Kyu-Hyun LEE
  • Publication number: 20180264082
    Abstract: The present invention relates to a method for treating anemia using a long-acting EPO formulation, and more specifically, a method for treating patients with anemia by confirmation of safe, long-acting, and optimal effective dosage and usage in administering a fusion polypeptide which comprises an EPO and an immunoglobulin hybrid Fc to patients with anemia. The method of administering the fusion polypeptide employs an appropriate dosage and usage which not only shows an excellent long-acting property compared to the existing EPO products but also minimizes cardiovascular side effects that may occur due to a rapid increase in hemoglobin level, which is an effect of anemia treatment.
    Type: Application
    Filed: January 8, 2016
    Publication date: September 20, 2018
    Applicants: GENEXINE, INC., GREEN CROSS CORPORATION
    Inventors: Sang-In YANG, Jung-Won WOO, Se Hwan YANG, Young Chul SUNG, Doo Hong PARK, Min Woo KIM
  • Patent number: 9988372
    Abstract: The present invention relates to a novel crystalline form of 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and a pharmaceutical composition containing the same. The novel crystalline form of a compound according to the present invention exhibits excellent stability even in high-temperature and humidity environments, and thus can be favorably used to prevent or treat diseases, such as thrombosis, myocardial infarction, atherosclerosis, inflammation, stroke, angina pectoris, restenosis after angioplasty, and thromboembolism.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: June 5, 2018
    Assignees: GREEN CROSS CORPORATION, LEGOCHEM BIOSCIENCES, INC.
    Inventors: Soongyu Choi, Jungsub Choi, So-Hyun Yoon, Yoo Hoon Kim, Jae Yeon Kim, Suk Ho Lee, Young Lag Cho, Ho Young Song, Dae Yon Lee, Sung Yoon Baek, Sang Eun Chae, Tae Kyo Park, Sung Ho Woo, Yong Zu Kim
  • Publication number: 20180127733
    Abstract: Provided is a modified iduronate-2-sulfatase (IDS) gene constructed by inserting the nucleotide of SEQ ID NO: 2 into a wild-type IDS gene. In addition to being negatively charged, the improved IDS enzyme encoded by the modified gene exhibits a sufficient retention time in blood to target the bone, so that it is more effective for treating Hunter syndrome.
    Type: Application
    Filed: July 29, 2016
    Publication date: May 10, 2018
    Applicant: GREEN CROSS CORPORATION
    Inventors: Sy LEE, Sung-Ick PARK
  • Patent number: 9896672
    Abstract: A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: February 20, 2018
    Assignees: GREEN CROSS CORPORATION, MediGeneBio Corporation
    Inventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
  • Publication number: 20180030424
    Abstract: Provided is a modified iduronate-2-sulfatase (IDS) gene constructed by inserting the nucleotide of SEQ ID NO: 2 into a wild-type IDS gene. In addition to being negatively charged, the improved IDS enzyme encoded by the modified gene exhibits a sufficient retention time in blood to target the bone, so that it is more effective for treating Hunter syndrome.
    Type: Application
    Filed: July 29, 2016
    Publication date: February 1, 2018
    Applicant: GREEN CROSS CORPORATION
    Inventors: Sy LEE, Sung-Ick PARK
  • Patent number: 9856216
    Abstract: Provided is a compound of formula (I) as a TNIK (Traf2- and NCK-interacting kinase), IKK? (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the compound according to the present invention effectively inhibits TNIK, IKK? and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: January 2, 2018
    Assignee: GREEN CROSS CORPORATION
    Inventors: Soongyu Choi, Eun-Jung Park, Hee Jeong Seo, Younggyu Kong, Ickhwan Son, Sang-ho Ma, Man-Young Cha, Mi-Soon Kim, Kisoo Park
  • Publication number: 20170368175
    Abstract: The present invention provides a pharmaceutical formulation comprising an anti-epidermal growth factor receptor (EGFR) antibody. The pharmaceutical formulation has low turbidity, without showing aggregation or particle formation, even under accelerated conditions, and exhibits good stability. Therefore, the pharmaceutical formulation can be effectively used for the treatment of disorders such as cancer.
    Type: Application
    Filed: January 15, 2016
    Publication date: December 28, 2017
    Applicant: GREEN CROSS CORPORATION
    Inventors: Yong Woon CHOI, Yoo Hoon KIM, Jungsub CHOI
  • Publication number: 20170307630
    Abstract: Provided are a kit for measuring a titer of a human antibody, a humanized antibody, or a human Fc-fusion protein in human plasma or serum, and a method for measuring a titer of a human Fc-containing protein in human plasma or serum using the same, and more specifically, a kit for measuring a titer of human Fc-containing protein in human plasma or serum, the kit including a diluent for sample, a diluent for conjugate, and a cleansing solution and being used in analysis through an indirect enzyme-linked immunosorbent assay (indirect ELISA), and a method for measuring a titer of human Fc-containing protein in human plasma or serum using the same.
    Type: Application
    Filed: September 30, 2015
    Publication date: October 26, 2017
    Applicant: GREEN CROSS CORPORATION
    Inventors: Yong Won SHIN, Juho LEE, Jeong-Ae LIM, Ki Hwan CHANG, Min-Soo KIM
  • Publication number: 20170189473
    Abstract: A composition containing wall teichoic acid-attached peptidoglycan (WTA-PGN) as an active ingredient, a method for preventing or treating Staphylococcus aureus infectious diseases using the composition, and a method for preparing a soluble WTA-PGN which can be used as an active ingredient in the composition are provided. The composition of the present invention can be effectively used for preventing or treating Staphylococcus aureus infectious diseases by opsonophagocytosis due to antigen-antibody reaction and neutrophil-mediated phagocytosis due to T cell activation at the early stage of infection.
    Type: Application
    Filed: May 29, 2015
    Publication date: July 6, 2017
    Applicants: GREEN CROSS CORPORATION, PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION
    Inventors: Bok Luel LEE, Min Ja LEE, Jong-Ho LEE, Min Young SEONG, Dong Ho AHN, Kazue TAKAHASHI, Kenji KUROKAWA
  • Patent number: 9683029
    Abstract: The present invention provides an antibody that binds to the surface antigen (HBsAg) of hepatitis B virus (HBV) to neutralize the hepatitis B virus. The surface antigen-binding site of the antibody was found to play a very important role in viral replication, and when a mutation in the site occurs, viral replication is significantly inhibited, and thus at least HBV virus cannot cause a mutation in the site. In the present invention, it was confirmed by the use of patient-derived virus that the antibody of the present invention binds to either YMDD mutant hepatitis B virus, produced by conventional viral replication inhibitors, or G145R HBsAg mutants to which plasma-derived HBIG (hepatitis B immunoglobulin) does not bind. In addition, the in vivo effect of the antibody of the present invention was examined using chimpanzees which are unique animal models for hepatitis B virus. As a result, it was found that the antibody has the effect of neutralizing even wild-type hepatitis B virus in the in vivo model.
    Type: Grant
    Filed: July 8, 2013
    Date of Patent: June 20, 2017
    Assignee: GREEN CROSS CORPORATION
    Inventors: Se-Ho Kim, Kwang-Won Hong, Wong-Won Shin, Ki Hwan Chang
  • Publication number: 20170152251
    Abstract: The present invention relates to a novel crystalline form of 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and a pharmaceutical composition containing the same. The novel crystalline form of a compound according to the present invention exhibits excellent stability even in high-temperature and humidity environments, and thus can be favorably used to prevent or treat diseases, such as thrombosis, myocardial infarction, atherosclerosis, inflammation, stroke, angina pectoris, restenosis after angioplasty, and thromboembolism.
    Type: Application
    Filed: July 18, 2014
    Publication date: June 1, 2017
    Applicants: GREEN CROSS CORPORATION, LEGOCHEM BIOSCIENCES,INC.
    Inventors: Soongyu CHOI, Jungsub CHOI, So-Hyun YOON, Yoo Hoon KIM, Jae Yeon KIM, Suk Ho LEE, Young Lag CHO, Ho Young SONG, Dae Yon LEE, Sung Yoon BAEK, Sang Eun CHAE, Tae Kyo PARK, Sung Ho WOO, Yong Zu KIM